BlueRock Therapeutics has received permission from Health Canada to start a Phase 1 clinical trial evaluating DA01, an investigational cell therapy that aims to restore neurons lost to Parkinson’s disease. This clearance comes three months after the U.S. Food and Drug Administration (FDA) accepted the company’s request…
Aptinyx‘s Phase 2 clinical trial evaluating its investigational oral compound NYX-458 for the treatment of cognitive impairment and mild dementia associated with Parkinson’s disease is resuming patient screening after a temporary pause due to the COVID-19 pandemic. Recruitment is underway at multiple locations in the United States.
A neural map of the brain region central to Parkinson’s disease opens the possibility of new ways to treat this disorder and others that stem from damage to the nerve cells found there. The map, detailed in a recent study, might enable researchers to understand how specific nerve damage…
A new research project aims to determine whether medications developed to treat depression might be viable candidates for easing some troubling side effects of treatments for Parkinson’s disease, including levodopa. Parkinson’s is caused by the death or dysfunction of cells in the brain that make a neurotransmitter (brain signaling…
Invitae has launched a new genetic testing program, at no charge to participants, to test adults suspected of having — or at risk of developing — neurodegenerative disorders, including Parkinson’s disease. The Adult Neurodegenerative Disorders sponsored testing…
Exercise can slow early cognitive decline in Parkinson’s disease patients who have a variant of the APOE gene, called APOE4, a recent study has found. “Additional research is needed to confirm our findings, but these results would support the use…
New research suggests that brain inflammation is the likely reason antibody-based therapies are ineffective in clinical trials for people with Parkinson’s and Alzheimer’s diseases. The findings show that the binding of the antibody to its target protein — in the case of Parkinson’s disease the misfolded alpha-synuclein —…
Microbleeds found in the brains of people with Parkinson’s disease by magnetic resonance imaging (MRI) scans were associated with cognitive decline, a study demonstrated. Higher levels of a microbleed-associated biomarker also were found in patients with dementia. Moreover, a statistical analysis found the…
Inbrain Neuroelectronics has raised  $16.8 million in Series A financing to support moving into clinical testing a new neuromodulation device that uses computer learning to treat Parkinson’s disease and epilepsy. Electrodes for this next-generation neurostimulator are also based on graphene, a single layer of tightly bound carbon  atoms that allows…
A Parkinson’s Foundation indoor cycling event aimed at highlighting the benefits of exercise while raising money for Parkinson’s (PD) research returns on June 12 for its second year. Called the Parkinson’s Revolution, the cycling program will take place at studios in 25 cities — up from…
Get regular updates to your inbox.
